Merck presentation.


Published on

Strategic Management.

  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • About Merck
Merck is a global research-driven pharmaceutical company dedicated to putting patients first.Merck had originally founded in 1668 in Germany, and established in 1891 in U.S.A. and in its early years, we were selling medicines. Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs.  The Company devotes extensive efforts to increase access to medicines through far-reaching programs that donate our medicines but help deliver them to the people who need them.
  • there are many programs in our company that help us to deliver medicines to people who need them, and these are some of Merck Patient Assistance Program, we provided free medicines to whocould not afford them. Medicines for chronic conditions that affect millions – like diabetes, asthma and high blood pressure.In 2008, approximately 1.5 million prescriptions were filled under the Merck Patient Assistance Program. Merck Prescription Discount Program for the uninsured people, they can save from 15 to 20 % off and it is easy to access by filling a 1 page application. we have a research program for HIV, Merck and University of Cape Town and Tertiary School of Business Administration, have been in partnership since 2004 to implement an HIV and AIDS curriculum for students in underserved communities in Cape Town, South Africa.Merck Medical Outreach Program. Founded in 1958, and it is one of the ways Merck helps to expand access to medicines and vaccines, especially in the developing world.
  • Merck has made an initial contribution of $450,000 to assist relief efforts through many organizations such as project HOPE and the American Red Cross.We also are donating needed medicines through our Merck Medical Outreach Program.we also allowing our employees who are licensed health professionals or allied health services providers, to take one paid week and participate on the ground in Haiti with non-profit organizations
  • Our products: we cover many areas in pharmaceutical industry from vaccines, prescription products, Consumer Products and Animal Health.we have 15 different vaccines , 40 prescription products and 17 Consumer products and we offer a broad choice of vaccines, anti-infective and anti parasitic drugs for animal health.
  • as we mentioned before about drug discovery stages, after we get the approval from (FDA), we can proceed with other procedures such as piblishing, manufacturing and marketing and sales as you can see the value chain of the industry.
  • Today’s Merck: Merck and Schering-Plough recently merged to create a new company. Today, we are the second-largest pharmaceutical company in the world by market share. We also are a global leader in consumer products and animal care. Both Merck and Schering-Plough have a long and rich history of working in pharmaceutical industry. and we are enthusiastic about the future of this new companyour merger will helps improve research and development productivity and offer cost savings opportunities and new products to help companies manage through lean times. what happened is the CEO made a hard decision, to eliminate some of the duplication jobs. “We have taken the best from both companies, from a process standpoint and a people standpoint.” the CEO Clark statedBiotech medicationsLast December, Merck launched a new division called Merck BioVentures to make both new and follow-on, generic, biotech drugs. They are starting to show up in Europe, but are not yet allowed in the U.S.This is one of areas that Merck is targeting for growth. "At Merck we continue to execute on our strategy of expanding our biopharmaceutical expertise and manufacturing capacity.AcquisitionAvecia Biologics is a contract manufacturing organization with specific expertise in microbial-derived biologics. Financial details of the transaction were not disclosed.
  • Certain of the Company’s major products are going to lose patent protection in the near futureThe Company is dependent on its patent rights, and if its patent rights are invalidated, the business would be adversely affected. another fact that The Company’s products, including products in development, can not be marketed unless the Company obtains and maintains regulatory approval.
  • Roberto gallo, Litton industry, Nixon, Kissinger, bio weappon-
  • Roberto gallo, Litton industry, Nixon, Kissinger, bio weappon-
  • Merck presentation.

    1. 1. Bakry Al-kafMatteoNebioloVietti<br />
    2. 2. Index<br />About Merck.<br />Merck’s Programs.<br />Today’s Merck.<br />The Global Pharmaceutical Industry.<br />Financial information.<br />
    3. 3. About Merck<br />global research-driven pharmaceutical company<br />Originally founded in 1668 in Germany.<br />Established in 1891 in U.S.A.<br />Its commitment to help all patients obtain access to the Merck medicines they need.<br />
    4. 4. Merck Programs<br />Merck Patient Assistance Program.<br />Free medicines.<br />1.5 million prescriptions.<br />Medicines for chronic conditions.<br />Merck Prescription Discount Program.<br /> For the uninsured.<br /> Saving of 15% to 20% off.<br /> Easy to access.<br />Merck's HIV research Program.<br />Merck Medical Outreach Program. <br />
    5. 5. Merck's Contributionin Haiti Relief Efforts<br />In response to this disaster.<br />Initial contribution.<br />Donating needed medicines.<br />Participation on the ground.<br />
    6. 6. Our Products<br />Vaccines<br />Prescription Products<br />Animal Health<br />Consumer Products<br />
    7. 7. From Laboratoryto Pharmacy Shelf<br />Drug Discovery<br />Preclinical Testing<br />Investigational New Drug (IND) Application<br />Clinical Trials<br />Phase I<br />Phase II<br />Phase III<br />Phase IV<br />Approval Review<br />
    8. 8. The Pharmaceutical Industry<br />Value Chain<br />
    9. 9. Current Strategies<br />Merger with Schering-Plough.<br />Job cuts follows the merger.<br />Biotech medications.<br />acquisition. ( Merck buys Avecia)<br />Diversification.<br />Innovation.<br />
    10. 10. Risks<br />Vioxx lawsuits issue.<br />Withdrawn in 2004.<br />4 billion Settlement agreement charge.<br />Certain of the Company’s products are going to lose patent protection.<br />
    11. 11. Competitors<br /> COMPANY COUNTRY TOTAL REV M USD % R&D<br />Switzerland 53,324 - 13% <br /> USA 48,371 – 1 6% <br />BayerGermany 44,2 - 4% <br />GlaxoSmithKline United Kingdom - 42,813 - 15% <br />Johnson and Johnson USA 37,02 - 14% <br />Sanofi-Aventis France 35,645 - 16% <br />Switzerland 33,547 - 16% <br />AstraZeneca UK/Sweden 26,475 - 15% <br />Merck & Co. USA 22,636 - 21% <br />
    12. 12. Competitors<br />
    13. 13. Competitors<br />
    14. 14. Financial Information<br />Annual Sales ($m)<br />
    15. 15. Financial Information<br />Material and Production Cost ($m)<br />
    16. 16. Financial Information<br />Net income as a % of sales<br />
    17. 17. Current Strategies<br /><ul><li>HIV chronological disease
    18. 18. Despite critics referring to Robert Gallo.
    19. 19. We won’t follow Italian/European HIV strategy even if we could (2007).
    20. 20. Don’t create definitive vaccine with stem cells
    21. 21. We make more money using Protease Inhibitors
    22. 22. FDA faster than EU bureacracy
    23. 23. Same for cancer</li></li></ul><li>Current Strategies<br />
    24. 24. Thank you<br />and<br />We are happy to answer your Questions<br />